Natural Capsules FY26: A Capsule Maker That Swallowed an API Subsidiary and Choked on the Overheads

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1 — At a Glance

For eight years Natural Capsules did one thing and did it steadily: make hard capsule shells, book a small profit, repeat. FY26 broke the pattern. Consolidated revenue rose 11% to ₹187.2 crore, and the operating line went the other way entirely — operating profit of ₹17.52 crore in FY25 became an operating loss of ₹1.56 crore in FY26. Below it, depreciation climbed 88% to ₹17.14 crore and finance cost rose to ₹10.95 crore from ₹6.54 crore. The result was a profit-before-tax loss of ₹27.92 crore and a net loss of ₹17.07 crore attributable to shareholders, against a ₹0.62 crore profit the year before.

The capsule business itself stayed profitable — the segment reported ₹20.82 crore of pre-interest profit. The drag sits one level down, in an API subsidiary that ran a full cost base against thin revenue. The segment split tells the story before any narrative does.

The market currently assigns the company no earnings multiple, because there are no earnings to divide into. It trades at 0.67 times book. A capsule maker that spent years compounding quietly now carries a factory that eats more than it earns. Which half wins the next two years is the whole question.

2 — Introduction

Natural Capsules Limited was incorporated in 1993 in Bangalore, listed on the BSE in 1994, and for three decades made hard two-piece gelatin and cellulose (HPMC) capsule shells — the empty containers other pharma companies fill. It is the first Indian maker of vegetarian capsules and describes itself as the second-largest domestic gelatin capsule manufacturer, running two plants at Bengaluru and Pondicherry.

The complication is a decision taken in 2020: to forward-integrate into steroidal APIs — Prednisolone, Betamethasone, Dexamethasone, Hydrocortisone and their derivatives — through a subsidiary, Natural Biogenex Private Limited, at a greenfield fermentation-and-synthesis plant in Tumkur. Three of those products sit under India’s PLI scheme.

The capex was large relative to the company. Fixed assets on the consolidated balance sheet jumped to ₹283.63 crore in FY25 from ₹102.76 crore a year earlier as the API facility was capitalised. Commercial API sales began only in Q4 FY26. The gap between spending on a plant and earning from it is exactly where FY26’s numbers were made — and lost.

3 — Business Model: WTF Do They Even Do?

Two businesses now live inside one listed entity, and they could not be more different in temperament.

The capsule business is the grown-up. It sells empty shells in sizes 00 through 4 to pharma and nutraceutical customers, exports ~28.94% of revenue, and books repeat business worth roughly 86% of turnover. Customers who have stayed more than ten years make up about 30% of the base. It is unglamorous, cash-generating, and did its job in FY26: the capsules segment earned ₹20.82 crore of pre-interest profit on ₹173.77 crore of revenue.

The API business is the toddler with an expensive appetite. Natural Biogenex makes fermentation-based steroidal APIs, is India’s sole approved producer of Dexamethasone and Betamethasone under the PLI list, and — as of FY26 — had a fully commissioned plant, a stack of depreciation, and ₹13.43 crore of annual revenue against it. The API segment posted a ₹31.33 crore pre-interest loss for the year.

So the model, plainly stated: a profitable shell-maker is funding a not-yet-profitable API plant, and the consolidated statements report the arithmetic of that subsidy. The strategic bet is that fermentation steroids — where the company positions itself as a rare end-to-end manufacturer outside China — eventually pay for the overheads they currently consume. The bet is unresolved.

Does a subsidiary that loses ₹31 crore on ₹13 crore of sales count as diversification, or as a second company the first one is carrying?

4 — Financials Overview

Figures are consolidated, in ₹ crore.

Q4 revenue rose 30% YoY and 55% QoQ. Management attributed the sequential jump largely to dispatches deferred from